Rephonic
Artwork for The Top Line
Artificial Intelligence
FDA
Biopharma
Clinical Trials
Oncology
Pharmaceutical Industry
Mergers and Acquisitions
Eli Lilly
Drug Development
Drug Pricing
Biotechnology
Pfizer
Cell Therapy
Gene Therapy
Alzheimer's Disease
Lung Cancer
Companion Diagnostics
Novo Nordisk
Women In Life Sciences
Patient Engagement

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

PublishesTwice weeklyEpisodes100Founded3 years ago
Number of ListenersCategories
Business NewsNews

Listen to this Podcast

Artwork for The Top Line

Latest Episodes

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.

In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pha... more

In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology developmen... more

In this episode of “The Top Line,” recorded on site at Fierce Biotech Week in Boston, Fierce’s Ayla Ellison sits down with Christelle Huguet, Ph.D., executive vice president and head of R&D at Ipsen, to discuss how the company is building its pipelin... more

In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or MRD, testing is beginning to redefine what early insight can mean in oncology drug develop... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Odd Lots
Odd LotsBloomberg

Recent Guests

Sheila Plant
Vice President, Regulatory Affairs
Allucent
Episode: FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
Christelle Huguet
Executive Vice President and Head of R&D at Ipsen
Ipsen
Episode: Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
Dale Muzzy
Chief Scientific Officer, Myriad Genetics
Myriad Genetics
Episode: Why MRD is becoming central to oncology drug development (Sponsored)
Lou Wellabob
Senior Vice President of Biopharma and Companion Diagnostics, Myriad Genetics
Myriad Genetics
Episode: Why MRD is becoming central to oncology drug development (Sponsored)
Amer Zeidan
Professor of Internal Medicine; Chief Division of Hematological Malignancies; Yale School of Medicine
Yale School of Medicine
Episode: Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Bruce Beutel
CEO, founder of PassKey
PassKey
Episode: Boston, China and the future of biotech
Ben Bradford
Head of external affairs
MassBio
Episode: Boston, China and the future of biotech
Uli Stilz
Joined Flagship Pioneering; previously BioInnovation Hub and Novo Nordisk external innovation
Flagship Pioneering
Episode: Boston, China and the future of biotech
Jeremy Richardson
Chief Commercial Officer at GiftHealth
GiftHealth
Episode: Why direct-to-patient is the future of pharma access (Sponsored)

Hosts

Ayla Ellison
Host covering policy, market trends, and business implications in biopharma and medtech.
Kelly Hogan
Host focusing on industry trends, deal-making, and strategic insights within biotech and pharma media coverage.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Why MRD is becoming central to oncology drug development (Sponsored)
Q: Where do biopharma teams struggle most when it comes to diagnostics today?
The guests argue that integration timing is critical—early engagement is key, with flexible assays that can adapt to the drug program rather than a one-off companion diagnostic late in development.
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Q: What makes Mesotoclax pharmacologically distinct from Venetoclax, and how might that translate into clinical practice?
Mesotoclax appears more potent with a threefold exposure advantage, strong BCL2 selectivity, less risk of myelosuppression from circulating metabolites, and a pharmacokinetic profile less affected by food or concomitant drugs, which could translate into higher efficacy with a more favorable safety profile in older patients.
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Q: Given the 100% objective response rate in the ASCO 2026 presentation, how should clinicians interpret these early results for Mesotoclax in HR-MDS and in frontline AML?
The data are extremely encouraging but must be interpreted with caution; the high response rates in a small, selected patient group suggest Mesotoclax could address unmet needs, particularly in safety and tolerability for older patients, but confirmatory randomized data are needed to establish durable survival benefits and to define where it fits in the treatment paradigm.
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
Q: Kristen, thank you so much for joining this episode today. What gave BioAge conviction in the aging-biology approach to drug development?
The conviction comes from observing that aging-related biology underlies multiple diseases, and that human data has validated targets in other areas. By studying long-term human data and leveraging biobanks, BioAge can identify targets tied to aging that are predictive of future disease risk and longevity, providing a foundation for a platform that translates aging biology into therapies.
Designing an agentic, future‑ready tech roadmap for emerging pharma (Sponsored)
Q: What common mistakes do emerging pharma organizations make when designing their technology roadmap?
The speaker highlights three main pitfalls: chasing AI trends without solid data readiness, operating within a fragmented, siloed ecosystem that leads to shadow IT, and underinvesting in integration and interoperability, which results in isolated tools rather than an integrated workflow. A fourth point is the pre-commercial paralysis—delaying data architecture and MDM design until late in the process.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Top Line

What is The Top Line about and what kind of topics does it cover?

A fast-moving, business-focused show that breaks down biopharma, medtech, and healthcare policy through interviews, expert analysis, and sponsor-driven conversations. Episodes frequently tackle pricing dynamics, regulatory shifts, supply-chain resilience, and go-to-market strategies for drugs, biologics, and medical devices. Notable throughlines include impact of tariffs and trade policy on global supply chains, rapid advances in RNA therapeutics and biomarker-driven trials, and the practical challenges of scaling manufacturing, clinical operations, and commercialization in a highly global, geopolitically nuanced landscape. The format blends newsroom-style reporting with in-depth guest discussions, offering listeners actionable takeaways fo... more

Where can I find podcast stats for The Top Line?

Rephonic provides a wide range of podcast stats for The Top Line. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Top Line and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Top Line get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for The Top Line, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Top Line?

Rephonic provides comprehensive predictive audience data for The Top Line, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Top Line have?

To see how many followers or subscribers The Top Line has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Top Line?

These podcasts share a similar audience with The Top Line:

1. BioCentury This Week
2. The Readout Loud
3. Biotech Hangout
4. The Long Run with Luke Timmerman
5. Odd Lots

How many episodes of The Top Line are there?

The Top Line launched 3 years ago and published 100 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Top Line?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Top Line?

Rephonic pulls ratings and reviews for The Top Line from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Top Line?

Rephonic provides full transcripts for episodes of The Top Line. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Top Line?

Recent guests on The Top Line include:

1. Sheila Plant
2. Christelle Huguet
3. Dale Muzzy
4. Lou Wellabob
5. Amer Zeidan
6. Bruce Beutel
7. Ben Bradford
8. Uli Stilz

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days